Before buying more leads, price the return visit.

Start with the care that is already due

A patient has an unfinished course of treatment. A review is overdue. An owner has not brought their pet back for preventive care. These are specific reasons to contact someone who already knows the practice. They are very different from trying to create interest in a service for the first time.

The existing relationship can reduce the work needed to arrange a visit. It does not make every old record a commercial opportunity. Some people have moved, completed care elsewhere, declined treatment or opted out. Start with an eligible group and a genuine reason to return, confirmed against the clinic’s records and contact permissions.

That distinction improves both the experience and the economics. A smaller, relevant cohort is more useful than a huge database whose size looks impressive in a presentation. The question is how much appropriate care can be brought forward, not how many numbers you can dial.

A €150 booking is not a €150 attended visit

Suppose your all-in acquisition cost is €150 per new-patient booking. That is an illustrative input, not a market benchmark. If 75% of those patients attend, the acquisition cost is €200 per attended visit: €150 divided by 0.75. The two numbers describe different outcomes.

Now compare a reactivation campaign against the same endpoint. Include the provider fee, calls, messages, integration allocation, campaign preparation and human follow-up. Include any other acquisition costs missing from your original comparison. Cheap transport is not the full cost of bringing someone back.

The calculator below uses fictional, editable inputs. It compares acquisition and reactivation at attendance, not at lead or booking. The control return rate represents normal care and existing outreach; it is not an instruction to withhold clinically necessary contact.

Do not claim the visits you did not create

In the example, 1,000 eligible patients receive the campaign and 160 attend. A comparable control group, receiving normal care but not the additional campaign, returns at 8%. Applied to 1,000 patients, that suggests 80 would have attended without the campaign. The estimated incremental effect is 80 visits, not 160.

At €6,000 all-in campaign cost, that is €75 per additional attended visit. Dividing by all 160 return visits would produce €37.50, a much more flattering number that answers the wrong question. The estimate depends on the comparison being credible.

Where appropriate, agree a randomised holdout before outreach, with the same eligibility criteria and observation window. Keep necessary care communications in both groups. Record other campaigns and prevent overlapping treatment. If individual assignment would contaminate the groups, consider a clinic-level or staged design with your analytics team.

A before-and-after comparison can be useful, but changes in season, staffing, appointment availability or advertising can explain part of the difference. Say so. A small sample also has uncertainty; an attractive point estimate is not a guarantee that the result will repeat at ten times the volume.

A cheaper visit still has to be worth serving

Cost per incremental visit is an operating measure, not profit. A consultation and a completed course of treatment have different economics. Use contribution after the costs of delivering the care, not the face value of an unsigned plan.

Suppose the 80 additional visits produce €100 of contribution each after care-delivery costs, before the reactivation campaign. That is €8,000. Subtract the €6,000 campaign cost and the incremental contribution is €2,000. At €50 contribution per visit, the same campaign loses €2,000. The phone performance has not changed. The business case has.

Do not add the advertising comparison to this contribution as another saving unless advertising spend is actually avoided without losing valuable demand. Nor should you count a signed plan as collected cash. Track treatment acceptance, delivery, payment and cancellations separately when you extend the model beyond attendance.

Check the diary before you scale the list

Reactivation is valuable when clinics can serve the additional demand. If it displaces patients who would have booked anyway, the apparent uplift may not be incremental at group level. If the next available appointment is too far away, extra bookings may not become extra visits.

Start with a cohort that matches real capacity: the right clinic, professional and appointment type. Review attended visits and the work generated for staff. Track opt-outs and complaints alongside conversion so a short-term revenue result does not hide damage to the relationship.

Repeated campaigns also change the pool. The first pass may reach the easiest-to-reactivate patients. A second pass is not automatically worth the same amount. Segment by the reason care is outstanding and measure again instead of applying the first campaign’s rate to the entire database.

Run a test that can change a budget decision

A useful pilot has a named cohort, a defined care need, a comparison group or defensible baseline, a fixed observation window and an all-in cost. Agree where attendance will be verified and how much extra work the clinic can absorb.

At the end, you should be able to decide whether to expand, change the workflow or stop. If all you receive is a count of calls and booked appointments, you have measured activity but have not answered the investment question.

Existing patients deserve attention because there is a relevant next step in their care. When that is true, reliable follow-up may be a better use of the next growth euro than buying another unfamiliar lead. Measure it before turning that possibility into a budget assumption.